Market Research Reports
Resources
About
Cart (0)

Antibiotic Resistance and Antibiotic Technologies: Global Markets

Report Code: PHM025B

Publish Date: Nov 2009

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

  • Overall sales in the current antibiotics and new products market were nearly $40 billion in 2008. It increased to $41.5 billion in 2009. By 2014, it is projected to increase to $65.5 billion, for a 5-year compound annual growth rate (CAGR) of 9.6%.
  • The largest segment antibiotic drugs market was nearly $36 billion in 2008; this further increased to $37 billion in 2009, this projected to reach $50 billion in 2014, for a 5-year CAGR of 5.9%.
  • Sales in the bacterial vaccines market amounted to $3.6 billion in 2008 which increased slightly to $3.9 billion in 2009. This is projected to increase to $15 billion in 2014, for a 5-year CAGR of 31.6%.

INTRODUCTION 

STUDY GOAL AND OBJECTIVES
 
The world is in the midst of an emerging crisis of antibiotic resistance to microbial pathogens. Numerous pathogens that have become resistant to commonly used antibiotics have been described in various contexts, including drug-resistant methycillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoneae, and Mycobacterium tuberculosis. Considering the breadth of effect and significant impact on morbidity and mortality, multi-drug-resistant (MDR) pathogens are a substantial threat to public health. Although this problem calls for the development of new antibiotics with new mechanisms of action, the pharmaceutical industry has abandoned the sector as less lucrative for their investments. The number of new antibiotics approved by the U.S. Food and Drug Administration (FDA) declined dramatically during the past 2 decades. 
During the past 5 years, there has been a revival in the antibiotics sector. Although some companies are developing analogues of existing antibiotic classes and putting them into clinical trials, other start-up and biotechnology companies have come up with molecules that adopt new approaches in tackling microbial infections. Although the number of such new molecules in the approval stages is still low, research and development (R&D) pipelines are promising, and several novel classes of antibiotics are in their early stages of development. The main goal of this report is to identify the trends in the antibiotics sector in terms of the emerging trends to handle the resistance problem worldwide. Most of the recent antibiotic clinical trials address the issue of antibiotic resistance. Hence, the market forecast based on conventional antibiotic classes will have a significant impact on both the newly approved drugs and the drugs in advanced stages of development targeting antibiotic resistance during the forecast period.
This report includes detailed analysis of the regulatory trends in various parts of the world. New legislation targeting antibiotic resistance issues are being considered by several governments. Impact of these trends can be significant in terms of the market forecast. The report also analyzes the nature, geographic spread, and mechanisms of various microbial infections. Various conventional and emerging antibiotic classes are analyzed in detail, and the mechanisms of action of these antibiotic classes are discussed. Mechanisms of resistance adopted by various bacteria are presented, along with the mechanisms chosen by scientists to counter the resistance mechanisms while designing new antibiotics. Emerging technology trends in the antibiotic sector are included as well. A detailed analysis of U.S. patents filed between 1976 and 2009 is conducted to identify the antibiotic classes that are gaining maximum attention by the research community and the key players investing in antibiotic R&D. Finally, the global antibiotic market size and its potential growth are estimated for the next 5 years. Because the market growth is mainly for the antibiotics tackling the resistance problem, the compound average growth rate (CAGR) indicates the growth of antibiotic resistance markets. 
REASONS FOR DOING THE STUDY
 
There is a renewed interest in the antibiotic sector, which is evident from the most recent patents and investments. Bacterial vaccines and new antibiotic classes are gaining a tremendous amount of attention with several product candidates in clinical development. These new products are expected to change the outlook of the antibiotic sector to a large extent over the next 5 years. Several reports focus on anti-infective markets in general. This report, however, focuses exclusively on antibacterials, with a particular emphasis on the emerging problem of antibiotic resistance. It also includes a detailed analysis of the emerging technology trends, which give a clear picture of the future of the sector. This helps to provide regulatory authorities and industry strategists a better perspective on which to base their decisions. BCC Research published a report on this topic in 2002. Since then, the market has witnessed dramatic changes in terms of technology, investment, and regulatory trends, which are captured in this report.   
INTENDED AUDIENCE
 
This report reviews the global antibiotic markets, including discussions on the market development and growth potential over the next 5 years. It also analyzes key factors that are driving the market growth. It describes the trends in detail with respect to various antibiotic classes, including the novel classes that are emerging and their technological basis. It includes in-depth discussions of the industry structure and the regulatory environment. It is valuable reading for investors, policymakers, and industry participants. Profiles of leading players in the industry are also included.
Such involved analyses have been conducted to help strategy developers and decision makers within pharmaceutical companies and government bodies. The detailed analyses of the regulatory factors that play major roles in deciding the industry trends are especially useful for legislators involved in government policy development programs. Technology trend and patent analyses give an overview of the new trends with respect to innovation within the sector. 
SCOPE OF REPORT
 
The scope of this report includes current antibiotic markets as well as the emerging antibiotic market, with an exclusive focus on antibiotic resistance. It technically encompasses antibacterials that include antibiotics, bacterial vaccines, and other emerging antibacterials that are not necessarily classified as antibiotics. Prevention of bacterial infections using bacterial vaccines is within the scope of the study. Antiviral and antifungal products are excluded from the market definition, and vaccines targeting viral diseases are outside the scope of this study. In short, this report contains:
  • Overview of antibiotic market
  • Classification of bacteria
  • Classification of antibiotics
  • Mechanisms of resistance by bacteria
  • Resistance trends and geographic analysis
  • Antibiotics targeted to counter the resistance mechanisms
  • Emerging regulatory trends
  • Technology trends in combating resistance
  • Patent analysis
  • Current antibiotic market and future growth trends
  • Emerging new approaches and product candidates in antibiotic resistance
  • Analysis of leading companies and their strategies
  • Sales projections through 2014 for antibiotic resistance markets
The base year of this study is 2009. Market figures are based on the revenues at the supplier levels, which are projected in 2009 constant dollars (i.e., inflation is not computed into the projection figures). The revenue figures are derived from the revenues of the key players in a particular year. Revenues of generic products are outside the scope of this study. Projections for the antibiotic resistance market are based on the assumption that the new and emerging products combat the antibiotic resistance issue in one way or another. Hence, forecasts are for the antibiotic resistance markets and are based mainly on the projections of the marketers. 
INFORMATION SOURCES AND METHODOLOGY
 
Both primary and secondary research methods were used in this market research study. The information and analysis presented in this report are based on an extensive survey of the antibacterial sector as well as a detailed examination of published literature and reports obtained from regulatory authorities, research institutions, trade associations, and national and international healthcare organizations. Key information from the literature was used to obtain expert opinion on commercial potential and market sizes from industry professionals. Data to prepare this study were derived from regulatory agencies, annual reports of companies, scientific associations, public healthcare authority websites, and industry related databases. In addition, discussion with researchers and sales personnel of drug companies, academic researchers, and government agency spokespersons have been conducted to gain insight into the emerging market trends. 
ANANLYST’S CREDENTIALS
 
Syamala Ariyanchira is a bench scientist who transferred to industry analysis. She combines her technical background with business sector issues and is involved in various activities, including technology assessment, strategic planning, competitor analysis, due diligence, and market analysis. Her clients include investment firms, government agencies, and chemical and pharmaceutical companies. She holds a PhD from Indian Institute of Science, Bangalore, India, and has authored three recent reports for BCC Research. 
BCC ONLINE SERVICES
 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
DISCLAIMER
 
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
[+] Show Chapter Details
Title/Chapter NamePagesMember Price
Full Report: Antibiotic Resistance and Antibiotic Technologies: Global Markets137Free
Chapter- 1: INTRODUCTION 5Free
Chapter- 2: EXECUTIVE SUMMARY3Free
Chapter- 3: OVERVIEW43Free
Chapter- 4: REGULATORY TRENDS16Free
Chapter- 5: PRODUCTS24Free
Chapter- 6: TECHNOLOGY TRENDS AND PATENT ANALYSIS11Free
Chapter- 7: INDUSTRY STRUCTURE35Free
Published - Feb-2002| Analyst - Lynn Gray| Code - PHM025A

Report Highlights

  • Worldwide, the total market for new and currently available antibiotics reached $22.3 billion in 2001. Average annual growth rate (AAGR) of 9.1%, this market will climb to $34.5 billion in 2006.
  • Growth will be driven by new products, whose sales will rise at an AAGR of more than 50% to $7.4 billion in 2006, representing 21% of the total market.
  • Sales in 2001 were just under $1 billion, just 4% of the market.
  • In 2001, the market for currently available antibiotics was $21.3 billion and is projected to increase at an AAGR of only 4.9% to $27.2 billion by 2006.
  • From 2001 to 2006, some 40 new products or formulations could be introduced into the antibiotics sector.
  • Many of these drugs will likely prove effective against infectious disease organisms that have developed multidrug resistances, rejuvenating the antibiotics market.

Related Reports

Recent Reports

Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - PHM204C

The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.

Rare Disease Diagnostics: Technologies and Global Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - PHM227B

The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.

Breakthrough Therapies: Market Dynamics and Investment Opportunities

Published - Dec 2024 | Publisher - BCC Publishing | Code - PHM176B

The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.

Softgel Capsules: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM244B

The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Top Trending Reports

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Medical Devices Industry: Competitive Landscape

Published - Nov 2024 | Publisher - BCC Publishing | Code - MDS010C

The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC239C

The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Antibiotic Resistance and Antibiotic Technologies: Global Markets
Customize This Report
Customize Report
Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.
Contact
© 2024 BCC Research
Privacy Policy |Site Map|Terms & Conditions